Pomegra
Eli Lilly (LLY) and Mastercard (MA) report before the open Thursday, with options pricing a 6.6% Lilly move on obesity-drug demand and spending in focus.
- Options markets imply a 6.6% move in Eli Lilly shares after its third-quarter report, due before the open on October 29.
- Lilly is expected to post about $22.6 billion in revenue, with Mounjaro and Zepbound near $15.1 billion combined.
- Mastercard is expected to report $5.15 to $5.17 per share on roughly $9.6 billion in revenue, up about 12%.
Lead
Eli Lilly and Mastercard both report third-quarter results before the U.S. market opens on Thursday, October 29. Options data compiled by Bloomberg put the implied post-earnings move for Lilly at 6.6%, roughly $85 on a share price near $1,282. Mastercard's options imply a smaller move of about 3.5%. The two reports give investors a read on two separate parts of the economy. One is demand for GLP-1 obesity and diabetes drugs. The other is how consumers are spending across borders and at home.What Is Priced In for Eli Lilly's Earnings?
The options market prices a swing of about 6.6% in either direction. Other trackers show slightly lower figures, between roughly 5% and 6.3%, depending on timing and method. Lilly shares are up about 18.7% so far this year.
Consensus calls for third-quarter revenue near $22.6 billion, about 28% above a year earlier. Mounjaro is projected at roughly $10.0 billion and Zepbound at about $5.0 billion. Together the two tirzepatide products account for about two-thirds of expected sales.
The bar is high. In the second quarter Lilly's revenue rose 48% to $23.0 billion. Mounjaro sales climbed 91% to $9.9 billion, and Zepbound rose 46% to $4.93 billion. The company raised its 2026 revenue guidance to $85.0 billion to $87.0 billion. It set non-GAAP earnings guidance at $35.50 to $36.50 per share, after absorbing $3.03 per share of acquired in-process research and development charges. Charges of that kind make per-share consensus unusually unstable, so revenue and product sales are likely to carry more weight than earnings per share.
Why Does Weight-Loss Drug Demand Matter So Much?
Weight-loss drug demand matters because it drives most of Lilly's growth. It also decides whether the company's valuation holds. Investors will look for volume growth that offsets lower net prices in the United States and in overseas markets.
The launch of the oral obesity pill Foundayo is a second focus. In the second quarter, total prescriptions doubled in a month, and nearly one in four were new patient starts. Management has pointed to wider commercial access and direct-to-consumer marketing as drivers.
The pipeline adds to the picture. On October 28, Lilly reported that retatrutide delivered a larger A1C reduction than the highest approved dose of Novo Nordisk's (NVO) Ozempic in a head-to-head trial. It also produced more than double the weight loss. The data strengthens Lilly's position against its main rival ahead of the call, which begins at 10 a.m. ET.
What Will Mastercard's Results Say About Consumer Spending?
Mastercard's report will show whether global consumer spending is holding up. Consensus expects earnings of about $5.15 to $5.17 per share, up from $4.38 a year earlier. Revenue is expected near $9.64 billion, a 12% rise.
Cross-border volume is the main swing factor. Growth slowed to 12% in the second quarter from 15% a year earlier, and consensus for the third quarter sits near 13%. Peer Visa (V) reported 10% growth in U.S. domestic purchase volume and 14% growth in cross-border volume on a constant-currency basis. That was better than expected and sets a favorable comparison.
Value-added services, which include cybersecurity and data products, are expected to grow near 20%, down from 25% a year ago. Operating margin was 61.1% in the second quarter, and consensus expects it to hold near that level. Mastercard has beaten earnings expectations for six straight quarters.
Market Context
Mastercard shares recently closed at a record $623.49 after an 11.5% gain over the month. That puts the stock near 31 times full-year 2026 consensus earnings, which leaves little room for disappointment. Credit quality is a related concern. American Express (AXP) is down about 15% this year on delinquency worries, so any comment from Mastercard on consumer health will be read closely. Cautious language on European spending or higher interest rates could weigh on the stock, while firm cross-border growth would support the premium multiple.
Outlook
Lilly's report will test whether volume growth in Mounjaro, Zepbound and Foundayo can keep the company on course for its $85.0 billion to $87.0 billion revenue target. The 6.6% implied move shows how much is riding on the result. Mastercard's results will show whether cross-border travel spending and U.S. consumer demand remain firm. Together, the reports feed into broader views of healthcare spending, consumer resilience and large-cap earnings momentum.
Mentioned tickers: LLY, MA, NVO, V, AXP
